

# ASX Announcement



21 April 2023

## MEB Executes Bridging Loans with Directors

**Melbourne, Australia, and Minneapolis, MN – 21 April 2023: Medibio Limited (MEB or the Company)** (ASX: MEB) (OTCPINK: MDBIF) is pleased to advise that the Company's two non-executive directors, Mr David Trimboli and Mr Christopher Ntoumenopoulos (**Directors**), have each entered into a Bridging Loan and agreed to advance a loan of \$100,000 each to the Company (each a **Bridging Loan** and together the **Bridging Loans**).

As disclosed in the Company's announcement on 15 February 2023 titled "MEB to Raise up to \$2.75 million By Way of a Placement & SPP", Messrs Trimboli and Ntoumenopoulos have partially underwritten the current Share Purchase Plan Offer (**SPP Offer**) up to \$350,000. For full details of the SPP Offer, please read the Prospectus dated and announced on 2 March 2023 in conjunction with the Supplementary Prospectus announced to the market on 14 April 2023 (**Prospectus**). Capitalised terms used throughout this announcement have the same meaning as given to them in the Prospectus unless the context requires otherwise.

The Company will be seeking shareholder approval on 23 May 2023, to amongst other things, approve the issue of SPP Shares and SPP Options to Messrs Trimboli and Ntoumenopoulos in relation to their partial underwriting of the SPP Offer. Full details of the extraordinary general meeting will be dispatched to shareholders and announced today.

### **Bridging Loan Material Terms**

Subject to the Company obtaining shareholder approval at the extraordinary general meeting to be held on 23 May 2023 (**EGM**), the Company may satisfy repayment of the amount outstanding under the Bridging Loans by either:

1. in the event that there is sufficient shortfall under the Shortfall Offer, the Directors respective loan amount will be offset against their respective Underwritten Amount by issuing Shortfall Shares and Shortfall Options; or
2. in the event that there is insufficient shortfall under the Shortfall Offer, issuing Shares and free attaching Options on the same terms as the SPP Shares (**Bridging Loan Shares**) and SPP Options (**Bridging Loan Options**).

In the event that shareholder approval is not obtained at the EGM and the Bridging Loans are not satisfied through the issue of Shortfall Shares or Bridging Loan Shares (as applicable) and free attaching Shortfall Options or Bridging Loan Options (as applicable), the Bridging Loans are repayable one year from the initial draw down of the Bridging Loans.

There will be no security granted by the Company in connection with the Bridging Loans which are subject to an interest rate of 5% per annum. Interest will be payable on the repayment date of the Bridging Loan but should that not occur before 31 December 2023 then an initial interest payment will be due on 31 December 2023.

There will be no other fees payable under the Bridging Loans.

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

**ENDS**

**Medibio Investor Enquiries:**

[investors@medibio.com.au](mailto:investors@medibio.com.au)

+61 8 6189 1155

**About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).